Wockhardt To Increase R&D Spending For Innovative Drugs, Founder Says
This article was originally published in PharmAsia News
Wockhardt's founder, chairman and CEO said the India drug maker plans to increase its research-and-development capabilities for innovative drugs over the next few years with a focus on the European and U.S. markets.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.